{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:08:52Z","timestamp":1790690932753,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PREMIER"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Acute heart failure (AHF) is accompanied by myocardial injury, wall stress, and systemic inflammatory activation. Whether initiating sacubitril\/valsartan (Sac\/Val) after haemodynamic stabilization modifies cardiac injury\/stress and systemic inflammatory biomarkers is uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Program Angiotensin-Neprilysin Inhibition in Admitted Patients with Worsening Heart Failure (PREMIER) study was a multicentre, prospective, randomized, open-label trial with blinded-endpoint assessment. Within 7 days of hospitalization and after haemodynamic stabilization, inpatients previously treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI\/ARB) were randomized to switch to Sac\/Val or continue ACEI\/ARB. In this pre-specified secondary analysis, high-sensitivity cardiac troponin T (hs-cTnT), soluble ST2 (sST2), C-reactive protein (CRP), and growth differentiation factor-15 (GDF-15) were measured at baseline and Week 8. N-terminal pro-B-type natriuretic peptide (NT-proBNP) was also assessed. Among 365 patients with complete cardiac injury\/stress and systemic inflammatory biomarker data, all biomarkers generally decreased over 8 weeks, but between-group differences in biomarker changes were not significant. In exploratory biomarker-stratified analyses, only baseline CRP showed a nominal treatment interaction for NT-proBNP (p for interaction=0.012).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In haemodynamically stabilized patients hospitalized for AHF, no differential effects of Sac\/Val vs. continued ACEI\/ARB therapy on cardiac injury\/stress and systemic inflammatory biomarkers were demonstrated over 8 weeks. These findings do not support a broad biomarker-defined anti-inflammatory or cardioprotective effect of Sac\/Val in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag076","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:54:19Z","timestamp":1789041259000},"source":"Crossref","is-referenced-by-count":0,"title":["Sacubitril\/valsartan and cardiac injury\/stress and systemic inflammatory biomarkers in acute heart failure: a pre-specified secondary analysis of the PREMIER study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-4138","authenticated-orcid":false,"given":"Shunichi","family":"Doi","sequence":"first","affiliation":[{"name":"Department of Cardiology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-7661","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University , 5-1-1 Nabeshima, Saga 849-8501 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-3467","authenticated-orcid":false,"given":"Takumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Organization for Clinical Medicine Promotion , Tokyo 112-0001 ,","place":["Japan"]},{"name":"Clinical and Translational Research Center, Kobe University Hospital , Kobe 650-0017 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University , 5-1-1 Nabeshima, Saga 849-8501 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiro","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tosei General Hospital , Seto 489-8642 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Ajioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tosei General Hospital , Seto 489-8642 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5189","authenticated-orcid":false,"given":"Takenori","family":"Ikoma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine , Hamamatsu 431-3192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine , Hamamatsu 431-3192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-8949","authenticated-orcid":false,"given":"Nobuhiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Medical University Hachioji Medical Center , Tokyo 193-0998 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-8525","authenticated-orcid":false,"given":"Yuya","family":"Matsue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine , Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-6016","authenticated-orcid":false,"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7670-7326","authenticated-orcid":false,"given":"Yoshihiro J","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-0939","authenticated-orcid":false,"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University , 5-1-1 Nabeshima, Saga 849-8501 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026092909403554900_pvag076-B1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","article-title":"Chronic heart failure and inflammation: what do we really know?","volume":"119","author":"Dick","year":"2016","journal-title":"Circ Res"},{"key":"2026092909403554900_pvag076-B2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nri3800","article-title":"Role of innate and adaptive immune mechanisms in cardiac injury and repair","volume":"15","author":"Epelman","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2026092909403554900_pvag076-B3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"2026092909403554900_pvag076-B4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","article-title":"Interleukin-6 in patients with heart failure and preserved ejection fraction","volume":"11","author":"Alogna","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026092909403554900_pvag076-B5","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation"},{"key":"2026092909403554900_pvag076-B6","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jchf.2024.04.016","article-title":"Autoimmune disorders in heart failure with preserved ejection fraction","volume":"12","author":"Tada","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026092909403554900_pvag076-B7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026092909403554900_pvag076-B8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026092909403554900_pvag076-B9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"2026092909403554900_pvag076-B10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41569-023-00919-6","article-title":"Immunomodulation and immunopharmacology in heart failure","volume":"21","author":"Markousis-Mavrogenis","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026092909403554900_pvag076-B11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092909403554900_pvag076-B12","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial","volume":"40","author":"Morrow","year":"2019","journal-title":"Eur Heart J"},{"key":"2026092909403554900_pvag076-B13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092909403554900_pvag076-B14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.059210","article-title":"Impact of sacubitril\/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE-MI echocardiographic substudy","volume":"146","author":"Shah","year":"2022","journal-title":"Circulation"},{"key":"2026092909403554900_pvag076-B15","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1093\/eurheartj\/ehae561","article-title":"In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial","volume":"45","author":"Tanaka","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092909403554900_pvag076-B16","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure\u2014digest version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"2026092909403554900_pvag076-B17","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J Card Fail"},{"key":"2026092909403554900_pvag076-B18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/jcdd10110468","article-title":"Soluble ST2 in heart failure: a clinical role beyond B-type natriuretic peptide","volume":"10","author":"Riccardi","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026092909403554900_pvag076-B19","doi-asserted-by":"crossref","first-page":"21672","DOI":"10.1038\/s41598-024-72137-0","article-title":"High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure","volume":"14","author":"Santas","year":"2024","journal-title":"Sci Rep"},{"key":"2026092909403554900_pvag076-B20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/ehf2.14271","article-title":"Prognostic value of growth differentiation factors 15 in acute heart failure patients with preserved ejection fraction","volume":"10","author":"Yin","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026092909403554900_pvag076-B21","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/SHK.0000000000000811","article-title":"Cardiac troponin release is associated with biomarkers of inflammation and ventricular dilatation during critical illness","volume":"47","author":"Ostermann","year":"2017","journal-title":"Shock"},{"key":"2026092909403554900_pvag076-B22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026092909403554900_pvag076-B23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cardfail.2025.05.001","article-title":"Uptitration of sacubitril\/valsartan in acute heart failure: insight from the PREMIER study","volume":"32","author":"Doi","year":"2026","journal-title":"J Card Fail"},{"key":"2026092909403554900_pvag076-B24","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ejhf.2664","article-title":"Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology","volume":"24","author":"N\u00fa\u00f1ez","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026092909403554900_pvag076-B25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026092909403554900_pvag076-B26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cardfail.2023.02.009","article-title":"Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society","volume":"29","author":"Tsutsui","year":"2023","journal-title":"J Card Fail"},{"key":"2026092909403554900_pvag076-B27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026092909403554900_pvag076-B28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.117.031560","article-title":"Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis","volume":"137","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"2026092909403554900_pvag076-B29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag076\/71030681\/pvag076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag076\/71030681\/pvag076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:40:48Z","timestamp":1790689248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article\/doi\/10.1093\/ehjcvp\/pvag076\/8790384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag076","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"pvag076"}}